Recently identified and potential targets for colon cancer treatment.
The systemic therapy for colorectal cancer has advanced from essentially a single, partially effective agent, 5-fluorouracil, to a combination of cytotoxics and antibodies offering increased survival. In addition to damage of DNA through agents, such as oxaliplatin and irinotecan, and inhibition of DNA replication, a promising approach involves modifying the control of gene expression, including epigenetic control. Modulation of invasion and metastasis should become increasingly important. Inhibition of growth-factor signaling with small-molecule drugs and antibodies can be a part of this effort. Further progress in the control of gene expression in colon cancer may be achieved with miRNAs and RNA interference if technical problems can be overcome. A number of genetic changes in colorectal cancer progression have been identified and offer targets for future therapy.
Lea
Michael A
MA
Department of Biochemistry & Molecular Biology, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA. lea@umdnj.edu
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D018450:Disease Progression; D016503:Drug Delivery Systems; D055808:Drug Discovery; D044127:Epigenesis, Genetic / Q000187:drug effects; D005419:Flavonoids / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006019:Glycolysis / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D035683:MicroRNAs / Q000187:drug effects / Q000235:genetics; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D016877:Oxidants / Q000627:therapeutic use; D010636:Phenols / Q000627:therapeutic use; D059808:Polyphenols; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000187:drug effects / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D000975:Antioxidants; D005419:Flavonoids; D056572:Histone Deacetylase Inhibitors; D035683:MicroRNAs; D009363:Neoplasm Proteins; D016877:Oxidants; D010636:Phenols; D059808:Polyphenols; D047428:Protein Kinase Inhibitors; D012334:RNA, Neoplasm